SanofiChengdu, Sichuan, China
Disclosure information not submitted.
409 - A Phase 3, Randomized, Modified Double-blind Study Demonstrates Immunological Superiority of High-Dose (HD) Over Standard-Dose (SD) Inactivated Influenza Vaccine (IIV) in Adults 50 Through 64 Years of Age
Tuesday, October 21, 20252:21 PM - 2:33 PM US ET
